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Introduction: Compared with the general population, cancer patients with venous thromboembolism 
(VTE) have higher rates of both VTE recurrence and bleeding. Low molecular weight heparins (LMWH) 
are the standard of care for the treatment of cancer-associated venous thromboembolism (CAT). Direct 
oral anticoagulants (DOACs) have recently emerged as a new therapeutic option, but optimal duration 
of therapy is still unclear. Decision for prolonged anticoagulation treatment is made individually as it 
depends on disease activity, current antineoplastic regime and patient risk-benefit profile1-3. 
Patients and Methods: A single center retrospective analysis of patients with CAT was conducted. The 
aim was to investigate type and duration of anticoagulation therapy. From our database of patients 
with VTE collected between 2016 and 2020, we included those with cancer associated deep venous 
thrombosis and/or pulmonary embolism. 
Results: The cohort consisted of 44 patients (40% women and 60% male), aged 20 to 91 years. Thera-
peutic options at discharge were LMWH in 60% cases (enoxaparin and dalteparin equally represented), 
VKA in 25% and DOAC in 15%. One patient was dismissed without anticoagulation because of an end-
stage gastric carcinoma which manifested as acute gastrointestinal bleeding. In follow-up period we 
observed that 20 patients (45%) had extended anticoagulation beyond 6 months: 50% LMWH, 30% rivar-
oxaban, 20% VKA. Among them, four patients initially treated with LMWH, were transited to rivaroxa-
ban because of reduced tolerability of parenteral drug. One case of major bleeding occurred (hematu-
ria) but there were no fatal or intracranial bleeding episodes in CAT patients on extended anticoagulant 
therapy in follow up period. 
Conclusion: Treatment of VTE in patient with cancer remains a clinical challenge. Guidelines recom-
mend at least 6 months of therapy for CAT and longer if the patient has active cancer or is receiving 
antineoplastic therapy. Extended anticoagulation may include LMWH or transition to an oral antico-
agulant. Since carcinoma carries both thromboembolic and bleeding risk, the decision should be made 
on a case-by-case basis. From our experience, that assumes regular clinical reassessments. 
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